A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Saved in:
Bibliographic Details
Title: A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
Authors: Palmer AC; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States., Chidley C; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States., Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, United States.; Department of Systems Biology, Harvard Medical School, Boston, United States.
Source: ELife [Elife] 2019 Nov 19; Vol. 8. Date of Electronic Publication: 2019 Nov 19.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2050-084X
DOI:10.7554/eLife.50036